These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38670720)

  • 1. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
    Ladouceur A; Ezdoglian A; Sparks JA; Hudson M; Jamal S; Clifford A; Roberts J; Ye C
    Rheum Dis Clin North Am; 2024 May; 50(2):181-199. PubMed ID: 38670720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging in Rheumatic Immune-related Adverse Events.
    Zhang J; Ni R; Oke I; Calabrese C; Strouse J; Weinmann S; Ladouceur A
    Rheum Dis Clin North Am; 2024 May; 50(2):313-323. PubMed ID: 38670729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor Associated Rheumatoid Arthritis.
    Bernabela L; Bermas B
    Curr Rheumatol Rep; 2024 Nov; 27(1):3. PubMed ID: 39589663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis.
    Gao J; Zhang P; Tang M; Nie X; Yuan Y; Yang F; Li L
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8993-9006. PubMed ID: 37160811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
    Quinn CM; Rajarajan P; Gill AJ; Kopinsky H; Wolf AB; de Camargo CS; Lamb J; Bacon TE; Murray JC; Probasco JC; Galetta KM; Kantor D; Coyle P; Bhise V; Alvarez E; Conway SE; Bhattacharyya S; Kister I
    Neurology; 2024 Dec; 103(11):e210003. PubMed ID: 39541548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system.
    Liu R; Zhao H; Lu Z; Zeng L; Shi H; Wu L; Wang J; Zhong F; Liu C; Zhang Y; Qiu Z
    Clin Exp Med; 2024 Sep; 24(1):216. PubMed ID: 39249163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of immune checkpoint inhibitors for cancer treatment.
    Arafat Hossain M
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113365. PubMed ID: 39447408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital ischemia: a rare immune-related adverse event of immune checkpoint inhibitors-case report and review of the literature.
    Yerolatsite M; Torounidou N; Venetsanopoulou AI; Zarkavelis G; Mauri D; Voulgari PV
    Rheumatol Int; 2024 Dec; 44(12):3141-3149. PubMed ID: 39230686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
    Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
    Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supporting People Treated with Immune Checkpoint Inhibitors: A Qualitative Study Exploring Oncology Healthcare Professionals' Experiences.
    Watts T; Jennings S; Anstey S; Roche D
    Semin Oncol Nurs; 2024 Dec; 40(6):151745. PubMed ID: 39482207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma.
    Tamura K; Takenaka Y; Hosokawa K; Sato T; Tsuda T; Eguchi H; Suzuki M; Fukusumi T; Suzuki M; Inohara H
    PLoS One; 2024; 19(11):e0314209. PubMed ID: 39585818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Musculoskeletal ultrasound characteristics of checkpoint inhibitor-associated inflammatory arthritis.
    Nasrallah M; Challener G; Schoenfeld S; Matza M; Lawrence D; Mooradian MJ; Reynolds KL; Sullivan RJ; Kohler MJ
    Semin Arthritis Rheum; 2024 Dec; 69():152573. PubMed ID: 39547083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine release syndrome caused by immune checkpoint inhibitors: a case report and literature review.
    Zhang X; You Y; Zhang P; Wang Y; Shen F
    Future Sci OA; 2024 Dec; 10(1):2422786. PubMed ID: 39575654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity.
    Hendekli CM
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9375-9398. PubMed ID: 37076644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare workers' informal uses of mobile phones and other mobile devices to support their work: a qualitative evidence synthesis.
    Glenton C; Paulsen E; Agarwal S; Gopinathan U; Johansen M; Kyaddondo D; Munabi-Babigumira S; Nabukenya J; Nakityo I; Namaganda R; Namitala J; Neumark T; Nsangi A; Pakenham-Walsh NM; Rashidian A; Royston G; Sewankambo N; Tamrat T; Lewin S
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD015705. PubMed ID: 39189465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
    Tramacere I; Virgili G; Perduca V; Lucenteforte E; Benedetti MD; Capobussi M; Castellini G; Frau S; Gonzalez-Lorenzo M; Featherstone R; Filippini G
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012186. PubMed ID: 38032059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis.
    Yang Y; Li L; Tian J; Ma L; Wu Y; Luo Q; Luo Y
    Front Pharmacol; 2024; 15():1453429. PubMed ID: 39588146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD007807. PubMed ID: 28752910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding?
    Posado-Domínguez L; Escribano-Iglesias M; Bellido-Hernández L; León-Gil JG; Gómez-Muñoz MA; Gómez-Caminero López F; Martín-Galache M; Inés-Revuelta SM; Fonseca-Sánchez E
    Curr Oncol; 2024 Nov; 31(11):7319-7329. PubMed ID: 39590170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.